Enlivex Therapeutics (NASDAQ:ENLV) Earns “Hold” Rating from D. Boral Capital

Enlivex Therapeutics (NASDAQ:ENLV)‘s stock had its “hold” rating reissued by D. Boral Capital in a research report issued to clients and investors on Monday,Benzinga reports.

A number of other research firms have also recently commented on ENLV. HC Wainwright restated a “buy” rating and issued a $7.00 price target on shares of Enlivex Therapeutics in a report on Tuesday, September 2nd. Wall Street Zen upgraded Enlivex Therapeutics to a “sell” rating in a research note on Saturday, August 30th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Enlivex Therapeutics in a research report on Tuesday, November 11th. One equities research analyst has rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Enlivex Therapeutics presently has a consensus rating of “Hold” and an average price target of $10.00.

Enlivex Therapeutics Stock Down 3.9%

Shares of ENLV stock opened at $0.98 on Monday. The firm has a 50 day moving average of $1.05 and a 200-day moving average of $1.11. The company has a market cap of $23.81 million, a price-to-earnings ratio of -1.69 and a beta of 1.20. Enlivex Therapeutics has a 52 week low of $0.83 and a 52 week high of $2.10.

Institutional Investors Weigh In On Enlivex Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in ENLV. Jane Street Group LLC lifted its position in Enlivex Therapeutics by 527.4% in the 1st quarter. Jane Street Group LLC now owns 80,759 shares of the company’s stock valued at $78,000 after acquiring an additional 67,886 shares in the last quarter. Citizens Financial Group Inc. RI bought a new stake in Enlivex Therapeutics during the 3rd quarter worth approximately $241,000. Finally, Susquehanna International Group LLP bought a new stake in Enlivex Therapeutics during the 3rd quarter worth approximately $57,000. Institutional investors and hedge funds own 1.02% of the company’s stock.

About Enlivex Therapeutics

Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial.